Equities researchers at StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock. FibroGen Stock Up 6.